



Bioengineering Approaches for the Treatment of Cancer

Guest Editors:

Dr. Vaibhav Jain

Abramson Cancer Center,
Department of Medicine,
University of Pennsylvania,
Philadelphia, PA 19104, USA

Dr. Vito W. Rebecca

Department of Biochemistry and
Molecular Biology, Johns
Hopkins University Bloomberg
School of Public Health,
Baltimore, MD 21205, USA

Deadline for manuscript
submissions:

closed (15 July 2023)

Message from the Guest Editors

Biomedical engineering (BME) and molecular engineering (ME) are umbrella terms, which include but are not limited to the application of engineering principles to improve or solve problems in medicine and biology. While BME applies engineering principles utilizing physical tools for different applications including improved anticancer drug delivery to achieve a high concentration of anticancer agents directly to the tumor and to maximize the uptake of anticancer agents by cancer cells with minimum effect on bystander cells (e.g., using nanoparticles, hydrogels, micelles, and liposomes, etc.), and modeling the tumor microenvironment (3D models of cancer), ME is more closely related to engineering biomolecules to solve such problems. Some successful examples of ME for cancer involve engineering biomolecules such as DNA (gene therapy, CRISPR, etc.), RNA (microRNAs, aptamers, etc.), peptides and protein-peptide vaccines, antibody, antibody–drug conjugates, enzymes, T cell receptors for chimeric antigen receptor (CAR)-T cell therapy, etc.). This Special Issue will cover various bioengineering approaches which are being utilized to treat different types of cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)